Senior Correspondent, London
Ben's Feed
Oct 27, 2014
Oct 27, 2014
Oct 27, 2014

In race for Ebola vaccines, technical hurdles loom large

LONDON (Reuters) – Drugmakers sprinting to develop Ebola vaccines face a series of technical hurdles if they are to get millions of doses ready for use next year — even assuming clinical trials are successful.

The challenges include finding sufficient sterile capacity for filling and packaging finished vials, getting fast quality approvals from regulators, and building a supply chain in Africa for products that must be stored at minus 80 degrees Celsius.

Oct 27, 2014
Oct 24, 2014

AstraZeneca cancer drug pipeline gets boost from European green light

LONDON (Reuters) – AstraZeneca’s cancer drug pipeline received a boost on Friday, as European regulators recommended approval of an experimental medicine against ovarian cancer.

The green light from the European Medicines Agency (EMA) for olaparib, or Lynparza, is welcome news since the product hit a road bump in June when a U.S. panel voted against its accelerated approval.

Oct 24, 2014
Oct 24, 2014
Oct 23, 2014
Oct 23, 2014

Fixing ‘Ebolanomics’ in pursuit of vaccines and drugs

LONDON (Reuters) – As researchers from Africa to China to America race to develop vaccines and treatments to fight Ebola, health experts are grappling with the economics of a disease that until this year had been off the drug industry’s radar.

Whether or not effective drugs come in time to turn around the world’s worst epidemic of the virus ravaging three West African countries, the world will want stockpiles to protect against inevitable future outbreaks, experts say.

Oct 23, 2014
    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben